Oral semaglutide (Rybelsus®, Novo Nordisk, Bagsværd, Denmark), a glucagon-like Peptide-1 (GLP-1) analogue for the treatment of type 2 diabetes (T2D), was co-formulated with a permeation enhancer (PE), sodium salcaprozate (SNAC). Here, GCG is linked to type 2 diabetes mellitus.